| ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets AJ Souers, JD Leverson, ER Boghaert, SL Ackler, ND Catron, J Chen, ... Nature medicine 19 (2), 202-208, 2013 | 3286 | 2013 |
| Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study P Fenaux, GJ Mufti, E Hellstrom-Lindberg, V Santini, C Finelli, ... The lancet oncology 10 (3), 223-232, 2009 | 3108 | 2009 |
| Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial M Hallek, K Fischer, G Fingerle-Rowson, AM Fink, R Busch, J Mayer, ... The Lancet 376 (9747), 1164-1174, 2010 | 2454 | 2010 |
| Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia AW Roberts, MS Davids, JM Pagel, BS Kahl, SD Puvvada, JF Gerecitano, ... New England Journal of Medicine 374 (4), 311-322, 2016 | 2175 | 2016 |
| iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL M Hallek, BD Cheson, D Catovsky, F Caligaris-Cappio, G Dighiero, ... Blood, The Journal of the American Society of Hematology 131 (25), 2745-2760, 2018 | 1848 | 2018 |
| International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with> 30% blasts H Dombret, JF Seymour, A Butrym, A Wierzbowska, D Selleslag, JH Jang, ... Blood, The Journal of the American Society of Hematology 126 (3), 291-299, 2015 | 1386 | 2015 |
| Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial G Salles, JF Seymour, F Offner, A López-Guillermo, D Belada, L Xerri, ... The Lancet 377 (9759), 42-51, 2011 | 1280 | 2011 |
| Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia P Fenaux, GJ Mufti, E Hellström-Lindberg, V Santini, N Gattermann, ... Journal of clinical oncology 28 (4), 562-569, 2010 | 1191 | 2010 |
| Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project KR Carson, AM Evens, EA Richey, TM Habermann, D Focosi, JF Seymour, ... Blood, The Journal of the American Society of Hematology 113 (20), 4834-4840, 2009 | 1073 | 2009 |
| Venetoclax–rituximab in relapsed or refractory chronic lymphocytic leukemia JF Seymour, TJ Kipps, B Eichhorst, P Hillmen, J D’Rozario, S Assouline, ... New England Journal of Medicine 378 (12), 1107-1120, 2018 | 1041 | 2018 |
| The international consensus classification of mature lymphoid neoplasms: a report from the clinical advisory committee E Campo, ES Jaffe, JR Cook, L Quintanilla-Martinez, SH Swerdlow, ... Blood, The Journal of the American Society of Hematology 140 (11), 1229-1253, 2022 | 1030 | 2022 |
| Pulmonary alveolar proteinosis: progress in the first 44 years JF Seymour, JJ Presneill American journal of respiratory and critical care medicine 166 (2), 215-235, 2002 | 1020 | 2002 |
| Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP … S Branford, Z Rudzki, S Walsh, I Parkinson, A Grigg, J Szer, K Taylor, ... Blood 102 (1), 276-283, 2003 | 1008 | 2003 |
| Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study S Stilgenbauer, B Eichhorst, J Schetelig, S Coutre, JF Seymour, T Munir, ... The lancet oncology 17 (6), 768-778, 2016 | 977 | 2016 |
| Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease AW Roberts, JF Seymour, JR Brown, WG Wierda, TJ Kipps, SL Khaw, ... Journal of Clinical Oncology 30 (5), 488-496, 2012 | 974 | 2012 |
| Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma LE Abrey, TT Batchelor, AJM Ferreri, M Gospodarowicz, EJ Pulczynski, ... Journal of clinical oncology 23 (22), 5034-5043, 2005 | 958 | 2005 |
| Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study DM Ross, S Branford, JF Seymour, AP Schwarer, C Arthur, DT Yeung, ... Blood, The Journal of the American Society of Hematology 122 (4), 515-522, 2013 | 879 | 2013 |
| Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial K Fischer, J Bahlo, AM Fink, V Goede, CD Herling, P Cramer, ... Blood, The Journal of the American Society of Hematology 127 (2), 208-215, 2016 | 844 | 2016 |
| Obinutuzumab for the first-line treatment of follicular lymphoma R Marcus, A Davies, K Ando, W Klapper, S Opat, C Owen, E Phillips, ... New England Journal of Medicine 377 (14), 1331-1344, 2017 | 826 | 2017 |
| Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma MS Davids, AW Roberts, JF Seymour, JM Pagel, BS Kahl, WG Wierda, ... Journal of Clinical Oncology 35 (8), 826-833, 2017 | 806 | 2017 |